RecruitingPHASE1, PHASE2NCT06064890

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Studying Frontotemporal dementia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AviadoBio Ltd
Intervention
Intrathalamic AAV.PGRN administration(procedure)
Enrollment
18 enrolled
Eligibility
30-75 years · All sexes
Timeline
20232030

Study locations (19)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06064890 on ClinicalTrials.gov

Other trials for Frontotemporal dementia

Additional recruiting or active studies for the same condition.

See all trials for Frontotemporal dementia

← Back to all trials